Outlook Therapeutics Inc OTLK

$0.47 -0.03 (-5.15%)

Valuation

Market cap
113,958,000
Revenue TTM
$1,410,000
Net income TTM
$-62,420,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-4,426.95%
Debt to equity
-1.75

Trading

Volume
4,794,500
Avg volume
5,115,290
Day's range
$0.45 – $0.49
Shares out
243,448,000
Stochastic %K
12%
Beta
0.66
Analysts
Moderate Buy
Price target
$5.03

Price

Company profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outl...

Show more

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
609 619 3990
Website
https://outlooktherapeutics.com
Address
111 S. Wood Avenue, Unit #100, Iselin, United States

Latest news

Stocktwits

DidYouReadThis Nov 1, 2:16 PM
Would #cost or #financialpreference #count as a #clinicaldifference for #compounded bevacizumab #used in wet #AMD? $OTLK
0 replies
IniG Nov 1, 12:09 PM
$OTLK https://gatewaypa.com/api/policydisplay/download?key=PolicyItems/Clinical_Existing/Pdfs/BCBSKS_MPS_Lytenava_09_26.pdf
0 replies
IniG Nov 1, 11:51 AM
$OTLK Here Dr. Eichenbaum says even if compounders stop compounding Avastin he will himself pull it out from Avastin vial and inject it to patient's eye and they have already done that in the past when needed. I'm not worried such usage will be a challenge for Lytenava but I'm totally confused, how does he get reimbursed from the payer when he is using a cancer drug vial but for opthamology. What about the FDA regulation. Is all of this legal and reimbursable ?
1 replies
Tom2772 Nov 1, 10:05 AM
$OTLK If OTLK can achieve even a fraction of the commercial trajectory that motivated the company nearly ten years ago to develop a competitive product for a billion-dollar market, some user profiles here may find themselves looking rather foolish in the long run. Especially those who consistently dismiss every positive development and allow their persistent negativity to cloud their judgment of the company's actual potential.
0 replies
pfelgueiras Nov 1, 8:48 AM
$OTLK - LYTENAVA COVER INSURANCE REIMBURSEMENT IN KANSAS WILL BE EFECTIVE ON DECEMBER 1, 2926 (Under Blue Cross Blue Shield of Kansas (BCBSKS) and its Blue Access network) See more information about OTLK at: https://www.reddit.com/r/OTLK_Investors/
1 replies
ss65 Nov 1, 8:14 AM
$OTLK Prompt : Give me an unbiased opinion on KOD vs OTLK current stock price considering at which stage of their product life cycle they are in. If you think they are over or undervalued, briefly explain why and by how much for each? Use all you data logic based on similar industry and past precedents. I need answer in 3-4 sentences, one para each for KOD and OTLK. GEMINI : KOD is pre-commercial and overvalued by 45%-50% (a $2.5B-$3B premium). Driven by Phase 3 data, the market prices upcoming BLA filings as a guaranteed success. This ignores its 2023 clinical failure, a steep 101.8x P/B ratio, and pre-revenue risks. $OTLK is early-commercial and undervalued by 130%-150% (a $150M-$200M deficit). The sub-$130M cap is compressed by launch fears ahead of the April 2027 U.S. J-code. This ignores its 12-year exclusivity moat and a European launch with 46% QoQ unit growth.
2 replies
Bungfolio Oct 31, 8:05 PM
$OTLK Bottom line from link below. LFG!!!
1 replies
IniG Oct 31, 7:57 PM
$OTLK https://www.bcbsks.com/latest-news/pharmacy-medical-policy-updates-53
1 replies